VolitionRx (NYSE:VNRX) Now Covered by Analysts at StockNews.com

StockNews.com began coverage on shares of VolitionRx (NYSE:VNRXFree Report) in a research note published on Sunday morning. The firm issued a sell rating on the stock.

Separately, Cantor Fitzgerald reissued an overweight rating and issued a $2.50 price objective on shares of VolitionRx in a research note on Wednesday, March 27th.

View Our Latest Stock Report on VNRX

VolitionRx Trading Down 14.5 %

NYSE:VNRX opened at $0.75 on Friday. The business’s 50-day moving average is $0.80 and its 200 day moving average is $0.85. VolitionRx has a 12 month low of $0.55 and a 12 month high of $1.81. The company has a market capitalization of $61.55 million, a P/E ratio of -1.47 and a beta of 1.26.

VolitionRx (NYSE:VNRXGet Free Report) last issued its quarterly earnings data on Monday, May 13th. The company reported ($0.10) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.11) by $0.01. The firm had revenue of $0.17 million for the quarter, compared to analysts’ expectations of $0.27 million. On average, research analysts forecast that VolitionRx will post -0.4 earnings per share for the current year.

Institutional Trading of VolitionRx

A hedge fund recently bought a new stake in VolitionRx stock. Silverberg Bernstein Capital Management LLC bought a new stake in VolitionRx Limited (NYSE:VNRXFree Report) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 147,038 shares of the company’s stock, valued at approximately $105,000. Silverberg Bernstein Capital Management LLC owned 0.19% of VolitionRx at the end of the most recent quarter. 8.09% of the stock is owned by hedge funds and other institutional investors.

About VolitionRx

(Get Free Report)

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes.

Featured Stories

Receive News & Ratings for VolitionRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VolitionRx and related companies with MarketBeat.com's FREE daily email newsletter.